Skip to content 
Aim for cancer screening
Shihe Genomics and clinical-grade gene sequencers
Leading enterprise MGI
Reached a global strategic cooperation
MGI is one of the few companies in the world that can independently develop and mass-produce clinical-grade gene sequencers with different throughput from Gb to Tb, with operations in more than 100 countries and regions on six continents, and is a leading enterprise in the field of life science and biotechnology.
Nanjing Shihe Gene Biotechnology Co., Ltd. is a leader in oncology NGS technology in China, and has achieved key technological breakthroughs in precision diagnosis and treatment of tumors and early screening, and two innovative medical devices have been approved for marketing by the State Food and Drug Administration. Previously, Shiho Genomics had carried out the development of tumor-related products based on MGI’s multiple sequencing platforms.
According to the agreement, the two parties will jointly empower the Jinling Cohort, a large-scale prospective natural population early cancer screening project, to provide technical support for the development of early cancer screening in China, lead the industry in compliance, and promote more breakthroughs in the clinical transformation and application of high-throughput sequencing technology through complementary technological advantages.
In 2022, Jiangbei New Area and Shihe Genomics jointly created the “Jinling Cohort”, a public welfare project for early tumor screening, which provides continuous physical examination and early tumor screening services for citizens in the jurisdiction based on the early tumor screening technology independently developed by Shiho Genomics. So far, the project has provided corresponding services to 15,000 Nanjing citizens.
The strong alliance between Shiho Genomics and MGI will further accelerate scientific and technological innovation and clinical transformation of cutting-edge achievements, reduce testing costs, improve service efficiency, and help the high-quality and standardized development of tumor precision medicine.
Mu Feng, CEO of MGI, said that he hopes to bring more cutting-edge and cost-effective empowerment to Shihe Genomics based on the cost advantage and wide compatibility of MGI’s platform, and bring breakthrough applications to the field of tumor precision medicine.
In the future, the two parties will focus on key areas such as basic clinical research, instrument and reagent registration and certification, clinical application and promotion, tumor precision medicine, and early cancer screening and diagnosis, and build an innovative foundation for tumor precision medicine based on MGI’s gene sequencing platform, laboratory automation platform, information management platform and other hardware support.
In addition, the two parties will also work together to achieve deep integration of technology and application in technology R&D and innovation, product and service development, global market expansion and brand building, industry policy research and standard formulation, international cooperation and exchanges.
In the future vision of the cooperation between Shiho Genomics and MGI, the construction of industrial ecology is placed in an important position. In fact, in the biomedical valley, the main position of the biomedical industry in the new area, a characteristic innovation system of the whole industry chain of life and health has been initially formed, among which the leading industry is the gene and cell industry, where many scientific and technological teams like Shihe gene are gathering, developing and growing.
For example, Zhenmai Biotech, which focuses on the R&D and manufacturing of gene sequencers, will launch new products within one year of landing in the new area, and is currently stepping up preparations for product launches; Centstar Biotech, which has been deeply involved in the field of glycomics for a long time, independently developed the first tumor auxiliary diagnostic product based on glycomics technology in China, and recently won the registration certificate of Class III medical devices from the State Food and Drug Administration and was approved for marketing…… When excellent enterprises gather into a trend, more and more good news in the industrial chain will follow.
